Jane R Schwebke1, Renee Desmond. 1. Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
Abstract
OBJECTIVE: The purpose of this study was to determine whether treatment of bacterial vaginosis (BV) decreases the incidence of sexually transmitted diseases (STDs). STUDY DESIGN:Women with asymptomatic BV were studied prospectively to determine the effect of treatment of BV for the prevention of STD. Women were assigned randomly to observation or treatment and prophylaxis with intravaginal metronidazole gel. Women were screened monthly for STDs. RESULTS: Women who were assigned randomly to receive metronidazole gel had a significantly longer time to the development of STDs compared with women in the observation group (P = .02). The 6-month STD rate was 1.58 per person-year (95% CI, 1.29, 1.87) for women in the metronidazole gel group vs 2.29 per person-year (95% CI, 1.95, 2.63) for women in the observational group. The difference in STD rates was driven by a significant difference in the number of chlamydial infections (P = .013). CONCLUSION: Treatment and twice-weekly prophylactic use of intravaginal metronidazole gel resulted in significantly fewer cases of chlamydia.
RCT Entities:
OBJECTIVE: The purpose of this study was to determine whether treatment of bacterial vaginosis (BV) decreases the incidence of sexually transmitted diseases (STDs). STUDY DESIGN:Women with asymptomatic BV were studied prospectively to determine the effect of treatment of BV for the prevention of STD. Women were assigned randomly to observation or treatment and prophylaxis with intravaginal metronidazole gel. Women were screened monthly for STDs. RESULTS:Women who were assigned randomly to receive metronidazole gel had a significantly longer time to the development of STDs compared with women in the observation group (P = .02). The 6-month STD rate was 1.58 per person-year (95% CI, 1.29, 1.87) for women in the metronidazole gel group vs 2.29 per person-year (95% CI, 1.95, 2.63) for women in the observational group. The difference in STD rates was driven by a significant difference in the number of chlamydial infections (P = .013). CONCLUSION: Treatment and twice-weekly prophylactic use of intravaginal metronidazole gel resulted in significantly fewer cases of chlamydia.
Authors: P Wølner-Hanssen; J N Krieger; C E Stevens; N B Kiviat; L Koutsky; C Critchlow; T DeRouen; S Hillier; K K Holmes Journal: JAMA Date: 1989-01-27 Impact factor: 56.272
Authors: N Sewankambo; R H Gray; M J Wawer; L Paxton; D McNaim; F Wabwire-Mangen; D Serwadda; C Li; N Kiwanuka; S L Hillier; L Rabe; C A Gaydos; T C Quinn; J Konde-Lule Journal: Lancet Date: 1997-08-23 Impact factor: 79.321
Authors: H Grosskurth; F Mosha; J Todd; E Mwijarubi; A Klokke; K Senkoro; P Mayaud; J Changalucha; A Nicoll; G ka-Gina Journal: Lancet Date: 1995-08-26 Impact factor: 79.321
Authors: Jennifer E Balkus; Lisa E Manhart; Jeannette Lee; Omu Anzala; Joshua Kimani; Jane Schwebke; Juma Shafi; Charles Rivers; Emanuel Kabare; R Scott McClelland Journal: J Infect Dis Date: 2016-02-04 Impact factor: 5.226
Authors: Jennifer E Balkus; Barbra A Richardson; Kishorchandra Mandaliya; James Kiarie; Walter Jaoko; Jeckoniah O Ndinya-Achola; Jeanne Marrazzo; Carey Farquhar; R Scott McClelland Journal: J Infect Dis Date: 2011-07-15 Impact factor: 5.226
Authors: Jennifer E Balkus; Walter Jaoko; Kishorchandra Mandaliya; Barbra A Richardson; Linnet Masese; Ruth Gitau; James Kiarie; Jeanne Marrazzo; Carey Farquhar; R Scott McClelland Journal: Sex Transm Dis Date: 2012-05 Impact factor: 2.830
Authors: Jane R Schwebke; Jeannette Y Lee; Shelly Lensing; Susan S Philip; Harold C Wiesenfeld; Arlene C Seña; Nikole Trainor; Nincoshka Acevado; Lisa Saylor; Ann M Rompalo; Robert L Cook Journal: Clin Infect Dis Date: 2015-11-26 Impact factor: 9.079